A Phase I/II Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer (Phase I) or Advanced Colorectal Cancer (Phase II).
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2015
At a glance
- Drugs Cetuximab (Primary) ; Erlotinib (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer; Head and neck cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.